GA NCORP

NCORP Trials

All Trials

1.
NCI Priority
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer Type
Lung Cancer
NCI ID
NCT02194738
Protocol IDs
NCI-2014-01509 (primary)
A151216
U10CA180821
U10CA031946
Treatment Sites (28)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
Marti Sears
404-236-8071
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Holly Holtzclaw
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
 
For a complete listing of all trial sites in Georgia, please visit GeorgiaCancerInfo.org
2.
NCI Priority
EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type
Eye Cancer, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCI ID
NCT02465060
Protocol IDs
EAY131 (primary)
NCI-2015-00054
EAY131-A
EAY131-B
EAY131-E
EAY131-F
EAY131-G
EAY131-H
EAY131-Q
EAY131-R
EAY131-U
EAY131-V
Treatment Sites (22)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
Marti Sears
404-236-8071
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Holly Holtzclaw
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo or Katelyn Ebert
404-303-3355
 
For a complete listing of all trial sites in Georgia, please visit GeorgiaCancerInfo.org
3.
NCI Priority
S1400 Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT02154490
Protocol IDs
S1400 (primary)
NCI-2014-00627
S1400E
S1400A
S1400C
S1400D
S1400B
U10CA180888
Lung-MAP
Treatment Sites (21)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
Marti Sears
404-236-8071
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Holly Holtzclaw
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
 
For a complete listing of all trial sites in Georgia, please visit GeorgiaCancerInfo.org
4.
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
Cancer Type
Breast Cancer
NCI ID
NCT01824836
Protocol IDs
E1Z11 (primary)
NCI-2013-00426
U10CA037403
Treatment Sites (2)
 
For a complete listing of all trial sites in Georgia, please visit GeorgiaCancerInfo.org
6.
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Cancer Type
Multiple Primaries
NCI ID
NCT01351545
Protocol IDs
10-CBA (primary)
Treatment Sites (4)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
 
For a complete listing of all trial sites in Georgia, please visit GeorgiaCancerInfo.org
7.
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies
Cancer Type
Leukemia
NCI ID
NCT02268851
Protocol IDs
14-396 (primary)
TGR-IB-105
Treatment Sites (1)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
8.
A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo-BM) for Patients With Hematologic Malignancies (BMT CTN #1101)
Cancer Type
Leukemia
NCI ID
NCT01597778
Protocol IDs
715 (primary)
2U10HL069294-11
Treatment Sites (3)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
 
For a complete listing of all trial sites in Georgia, please visit GeorgiaCancerInfo.org
9.
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3 / ITD AML
Cancer Type
NCI ID
NCT02997202
Protocol IDs
2215-CL-0304 (primary)
NCI-2017-01112
2016-001061-83
BMT CTN 1506
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
10.
A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT00078598
Protocol IDs
CCBX001-049 (primary)
Treatment Sites (0)
11.
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R / R) B-cell Non-Hodgkin Lymphoma (NHL)
Cancer Type
Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT02631044
Protocol IDs
017001 (primary)
NCI-2016-00057
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
12.
A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
Cancer Type
Leukemia
NCI ID
NCT02588092
Protocol IDs
ADCT-301-002 (primary)
NCI-2015-01928
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
 
For a complete listing of all trial sites in Georgia, please visit GeorgiaCancerInfo.org
13.
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (KEYNOTE-037/ ECHO-202)
Cancer Type
Bladder Cancer, Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Non-Hodgkin Lymphoma, Oral Cancer, Ovarian Cancer
NCI ID
NCT02178722
Protocol IDs
INCB 24360-202 (primary)
NCI-2015-01316
Treatment Sites (13)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
Marti Sears
404-236-8071
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Holly Holtzclaw
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
14.
A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
Cancer Type
Unknown Primary
NCI ID
NCT02658890
Protocol IDs
CA017-003 (primary)
NCI-2016-00153
2015-004914-79
Treatment Sites (2)
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
16.
A Phase 2, Randomized, Biomarker-driven, Clinical Study on Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Cancer Type
Leukemia
NCI ID
NCT02520011
Protocol IDs
TPI-ALV-201 (primary)
NCI-2015-02082
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
17.
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Cancer Type
Endometrial Cancer
NCI ID
NCT03077698
Protocol IDs
VX-EC-2-02 (primary)
NCI-2017-01875
Treatment Sites (2)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
18.
A Phase 2, Single-arm, Open-label Study of Single-agent Brentuximab Vedotin for Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above
Cancer Type
Hodgkin Lymphoma
NCI ID
NCT01716806
Protocol IDs
SGN35-015 (primary)
Treatment Sites (12)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
Marti Sears
404-236-8071
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Holly Holtzclaw
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
19.
A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients With AdvanCed Gastrointestinal Stromal TUmorS Who Have Received Treatment With Prior Anticancer Therapies
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT03353753
Protocol IDs
DCC-2618-03-001 (primary)
NCI-2018-00069
Treatment Sites (5)
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
20.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Cancer Type
Ovarian Cancer
NCI ID
NCT02655016
Protocol IDs
PR-30-5017-C (primary)
NCI-2016-00574
Treatment Sites (4)
Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Gynecologic Oncology
Atlanta
Jen Cuvo or Katelyn Ebert
404-303-3355
22.
A Phase I/IB Study of Ipilimumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT01822509
Protocol IDs
NCI-2013-00739 (primary)
12-537
9204
U01CA062490
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
24.
A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)
Cancer Type
Bone and Soft Tissue (including Sarcoma), Melanoma
NCI ID
NCT02775851
Protocol IDs
S1512 (primary)
NCI-2016-00666
Treatment Sites (2)
 
For a complete listing of all trial sites in Georgia, please visit GeorgiaCancerInfo.org
25.
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT02921256
Protocol IDs
NRG-GI002 (primary)
NCI-2016-00222
Treatment Sites (1)
For a complete listing of all trials matching your criteria in Georgia, please visit GeorgiaCancerInfo.org
1-25 of 107 Trials